NGM BIOPHARMACEUTICALS INC: key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2023)
- $4.4M
- Net Income/Loss (FY2023)
- -$142.4M
- Total Assets (FY2023)
- $168.9M
- Total Equity (FY2023)
- $148.6M
- Cash Flows from Operating Activities (FY2023)
- -$132.2M
Source: NGM BIOPHARMACEUTICALS INC 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
